Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OM-85 (OM Pharma, 4c7e20)
- Development stage
- Unknown
- Lead developer
- OM Pharma
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
OM-85 is an oral standardized bacterial lysate composed of lyophilized extracts from 21 strains of 8 common respiratory pathogens, including *Haemophilus influenzae*, *Streptococcus pneumoniae*, and *Staphylococcus aureus*. It acts as an immunomodulator by stimulating both innate and adaptive immune responses, primarily through the activation of Toll-like receptors (TLR2 and TLR4). This stimulation enhances airway epithelial barrier function, promotes antiviral properties, and induces immune tolerance. Marketed under brand names such as Broncho-Vaxom and Broncho-munal, it is indicated for the prevention of recurrent respiratory tract infections (RTIs) and acute exacerbations of chronic bronchitis. The Fondazione Policlinico Universitario Campus Bio-Medico is currently evaluating its efficacy in a Phase 4 clinical trial specifically targeting the reduction of lower RTIs in elderly nursing home residents aged 75 and older.
- Brand names
- Broncho-VaxomBroncho-munal
- Other names
- Bacterial lysateStandardized bacterial lysate
02
Targets
TLR2 (Toll-like Receptor 2)TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on OM-85 (OM Pharma, 4c7e20).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OM-85 (OM Pharma, 4c7e20).